Print this article
- 07/11/2017

Biotech company’s stock jumps 44% due to positive results for a treatment against a rare lung disease.

Pharma Horizon

Arena Pharmaceuticals  raised its stocks value as well as hope for patients suffering from the rare lung disease that its  experimental drug Ralinepag should help to cure. 

As soon as the company has annouced the positive results in phase 2 for the experimental drug Ralinepag, share went up more than 44%.

The drug so far met its primary Phase 2 program goal as patients  with pulmonary arterial hypertension showed a meaningful improvement in the conditions  as well as  greater pulmonary vascular resistance.

“These data give us confidence to move expeditiously toward a Phase 3 clinical program,” Arena chief medical officer Preston Klassen said.ù

Read the full press release


Source: CBNC